| Literature DB >> 32226378 |
Seyed Vahid Jasemi1, Hosna Khazaei2, Ina Yosifova Aneva3, Mohammad Hosein Farzaei2, Javier Echeverría4.
Abstract
BACKGROUND: Pulmonary hypertension (PH) is a progressive disease that is associated with pulmonary arteries remodeling, right ventricle hypertrophy, right ventricular failure and finally death. The present study aims to review the medicinal plants and phytochemicals used for PH treatment in the period of 1994 - 2019.Entities:
Keywords: herbal medicine; medicinal plants; phytochemicals; phytopharmacological review; pulmonary hypertension
Year: 2020 PMID: 32226378 PMCID: PMC7080987 DOI: 10.3389/fphar.2020.00145
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Medicinal plants used for Pulmonary Hypertension treatment.
| Medicinal plants (Scientific Name) | Effective dose | Extract/Part | Model | Animal/Cell | Outcome | References |
|---|---|---|---|---|---|---|
|
| 0.03% mix in food | Volatile oil/Bulb | _ |
| ↑eNOS, ↑Ca2+ influx in PAECs |
|
|
| 100 mg/kg | Aqueous extract/Garlic powder | Hypoxia |
| ↑NO, ↓PH |
|
|
| 2% mix in food | ND/Leaf | MCT |
| ↓RV/(LV + S), ↓MWT %, ↑PDE5A, ↑TAPSE |
|
|
| 0.2 mL/L drinking water | Flavonoid enrich extract/ND | High altitude |
| ↑BW, ↓PBP, ↑NO, ↓MDA, ↓hematocrit, ↓H:L ratio, ↓RVH |
|
|
| 0.2 mL/L drinking water | Extract mix in drinking water | High |
| ↓AST, ↓ALT, ↓ALP, ↑Albumin, ↑Globulin,↑Feed intake, ↓RV : TV ratio |
|
|
| 15 and 450 mg/kg | Ethanolic extract/tuber | MCT |
| ↑PA relaxation, ↓(RV/LV+S), ↓RVH |
|
|
| 0.75% mix in food | Mix in food/leaves and shoots | High altitude |
| ↑NO, ↓MDA, ↓H:L ratio, ↓Hematocrit, ↓ET-1, ↑SOD, ↑iNOS |
|
|
|
| Hydro methanolic extract/leaf | Hypoxia |
| ↑NO, ↓PAP, ↓RV/(LV+S), ↓p38, ↓.O- 2, ↓TNF-α |
|
|
| 4.5 mg/kg | Ethanol extract/leaves | MCT |
| ↓PABP, ↑SOD |
|
|
| 250 mg/kg | Bioactive enrich fraction | Hypoxia |
| ↓mPAP, ↓RVH, ↓PCNA, ↓cyclin D1, ↓CDK4, ↑p27Kip1, ↓pulmonary small artery wall thickness |
|
|
| 14 g/kg | Aqueous extract/Root | MCT |
| ↓PAP, ↓ET-1, ↓TXA2, ↑NO, ↑Prostacyclin, |
|
|
| ND | ND | Hypoxia |
| ↓Thickening in the SPAs, ↑HO-1, ↑NO, ↑iNOS, ↓eNOS |
|
|
| 0.33 mL/100 g BW | ND | Hypoxia |
| ↓RVSP, ↓RVHI |
|
|
| 4 g/kg | Supplementation of diet/seed | High altitude |
| ↑NO, ↓MDA, ↓T, R, S ECG waves, ↓RVH, ↑iNOS, ↑CAT, ↓ET-1 |
|
|
| 250 mg/kg | Aqueous extract/Stem bark | MCT |
| ↓SOD, ↑TBARS, ↑CAT, ↓NOX1, ↓BCL2/BAX ratio, ↓%MWT |
|
|
| 20 mg/kg | Isoflavones | Low temperature (12 ± 2°C) |
| ↓PAP, ↓ET-1, ↑iNOS |
|
|
| 100 mg/kg | Hydro-alcoholic extract/root | MCT |
| ↓RVP, ↓RVH, ↓ROS, ↓PCNA, ↑procaspase-3, ↑IL-10, |
|
Phytochemicals used for Pulmonary Hypertension treatment.
| Phytochemical | Effective dose | Model | Animal/cell | Outcome | References |
|---|---|---|---|---|---|
| Apiin | 5 mM/kg | Hypoxia |
| ↓PAP, ↓Aortic pressure |
|
| Apple polyphenol | 20 mg/kg | Hypoxia |
| ↓mPAP, ↓PVR, ↓Cytosolic Ca2+ in PASMC, ↓Caspase-3, ↓iNOS |
|
| Asiaticoside | 50 mg/kg | Hypoxia |
| ↑NO, ↓ET-1, ↑cGMP, ↑phosphorylation of serine/threonine- protein kinase/eNOS, ↓RVH,↓ mPAP, ↑PI3K/Akt/eNOS pathway |
|
| Asiaticoside |
| Hypoxia |
| ↓mPAP, ↓RVH, ↓TGF-β1, ↓TGF-βR1, ↓TGF-βR2, ↓Smad2/3 |
|
| Astragalus Polysaccharide | 200 mg/kg | MCT |
| ↓mPAP, ↓PVR, ↓RVH, ↑eNOS, ↑NO, ↓IL-1β, ↓IL-6, ↓TNF-α, ↓pho-IκBα |
|
| Baicalin | 30 mg/kg | Hypoxia |
| ↑ADAMTS-1, ↓Type I collagen, ↓RV/(LV + S)%, ↓ mSAP, ↓mPAP |
|
| Baicalein | 10 mg/kg | MCT |
| ↓RVSP, ↓RVH, ↓ET-1, ↓ETAR, ↑SOD, ↓Akt/ERK1/2/GSK3β/β-catenin, ↑eNOS, ↓vWF |
|
| Baicalin | 40 μg/L | TGF-β1 |
| ↓TGF-β1, ↓HPASMCs, ↓HIF-1α, ↓AhR |
|
| Berberine | 100 mg/kg | Hypoxia |
| ↓proliferation and migration of PASMCs, ↓RV/(lV + S), ↓Medial wall thickness, ↓PP2Ac |
|
| Carvacrol |
| Hypoxia |
| ↓RV/LV+S, ↓MDA, ↑SOD, ↑GSH, ↓Bcl-2, ↓Procaspase-3, |
|
| Genistein | 1 mg/kg | MCT |
| ↓RVP, ↑VEF, ↓RVEF, ↑ERβ |
|
| Ginsenoside Rb1 |
| Hypoxia and MCT |
| ↓ET-1, ↓SOCE, ↓RV(LV+S), ↑Relaxation |
|
| Isorhynchophyl line (IRN) |
| MCT |
| ↓Cyclin D1, ↓CDK6, ↑p27Kip1, ↓ERK1/2, ↓STAT3, ↓Akt/GSK3β, ↓RVP, ↓RVH |
|
| Luteolin | 5 mM/kg | Hypoxia |
| ↓PAP, ↓Aortic pressure |
|
| Magnesium lithospermate B |
| Hypoxia |
| ↓RVSP, ↓NOX2, ↓NOX4, ↓ERK, ↓ROS, ↓H2O2, ↓OPN, ↓Cyclin D1, ↑α-SMA, ↑SM22α |
|
| Nobiletin | 50 mg/kg | MCT |
| ↓RVSP, ↓RVH, ↓RV/(LV+S) ↓Src/STAT3, ↓PDGF-BB, ↓Src/STAT3 |
|
| Oxymatrine |
| MCT and hypoxia |
| ↓RVSP, ↓RV/[LV+S], ↓Cell number, ↓MCP-1, ↓IL-6, ↓SDF-1, ↓TGF-β, ↓VEGF, ↓ICAM-1, ↓VCAM-1, ↑SOD, ↑HO-1, ↑GSH, ↑Nrf2 |
|
|
| 50 mg/kg | Hypoxia |
| ↓PAP, ↓RV/(LV+S), ↓p-p38MAPK, ↓p38MAPK |
|
| Polydatin | 20 mg/kg | Hypoxia |
| ↓mPAP, ↓mCAP, ↓RVH, ↓Ang II, ↓ET, ↑NO |
|
| Punicalagin | 45 mg/kg | Hypoxia |
| ↓RVH, ↓mPAP, ↓RV/(LV+S), ↓MMP-9, ↓HIF-1α, ↓NF-kB, ↓TNF-α, ↓VEGFA, ↑SOD, ↑cGMP, ↑NO |
|
| Quercetin |
| Hypoxia |
| ↓PAH, ↓RVH, ↓Cell migration, ↑cyclin D1, ↓cyclin B1, ↓Cdc2, ↓MMP2, ↓MMP9, ↓CXCR4, ↓Integrin β1, ↓integrin α5, ↓TrkA/AKT signaling pathway, ↑BAX, ↓BCL2 |
|
| Quercetin | 100 mg/kg | MCT |
| ↓mPAP, ↓RVH, ↓PCNA, ↓WT |
|
| Resveratrol | 100 μM/L | Hypoxia |
| Inhibiting the PI3K/AKT signaling pathway, ↓p-Akt, ↓MMP-2 and MMP-9 |
|
| Resveratrol |
| Hypoxia |
| ↓RVSP, ↓HIF-1α, ↓ROS, ↓PH, ↓IL-6, ↓IL-1β, ↓TNF-α, ↓NF-κB |
|
| Resveratrol and Trimethoxystilbene | Resveratrol: 200 μM | TNF-α |
| ↓PASMCs, TMS was more potent compared with RES |
|
| Rhoifolin | 5 mM/kg | Hypoxia |
| ↓Cardiac output, ↓Aortic pressure |
|
| Salidroside |
| Hypoxia |
| ↓RVH, ↓BCl2, ↑Caspase-3, ↑BAX, ↑A2aR |
|
Figure 1Study design and extraction.
Figure 2The summary of 6 pathways that leads to PH improvement.
| 5-LOX | 5-lipoxygenase |
| 6-Keto-PGF1α | 6-keto prostaglandin F1α |
| A2aR | adenosine A2a receptor |
| α-SMA | α-smooth muscle actin |
| ADAMTS-1 | a disintegrin and metalloprotease with thrombospondin motif type I |
| Ang II | angiotensin II |
| AhR | aryl hydrocarbon receptor |
| Akt | protein kinase B |
| ALK-I | activin receptor like kinase 1 |
| ALP | alkaline phosphatase |
| ALT | alanine amino transferase |
| AST | aspartate amino transferase |
| BAX | BCL2-associated X protein |
| BCL2 | B-cell lymphoma-2 |
| BMPR2 | Bone morphogenetic protein type 2 receptor |
| BW | body weight |
| CAT | catalase |
| CAV-I | Caveolin-1 |
| Cdc2 | Cell division control protein 2 homolog 1 |
| CDK4 | cyclin protein kinase 4 |
| CDK6 | cyclin protein kinase 6 |
| cGMP | Guanosine 3′,5′ cyclic monophosphate |
| CTEPH | chronic thromboembolic pulmonary hypertension |
| CXCR4 | CXC chemokine receptor 4 |
| DMDS | Dimethyl disulfide |
| ECG | electrocardiogram |
| ENG | endoglin |
| eNOS | endothelial nitric oxide synthase |
| ERα | human estrogen receptor sub-type β |
| ERβ | human estrogen receptor sub-type β |
| ERK1/2 | extracellular signal-regulated protein kinases 1 and 2 |
| ET | endothelin |
| ET-1 | endothelin-1 |
| ETAR | endothelin A receptor |
| ET-1 | endothelin-1 |
| GSH | glutathione |
| GSK3β/β | glycogen synthase kinase 3 beta |
| GPx | glutathione peroxidase |
| H/L ratio | heterophil to lymphocyte ratio |
| HIF-1α | hypoxia-inducible factor 1α |
| HIV-1 | human immunodeficiency virus type 1 |
| HO-1 | heme oxygenase 1 |
| HP | Hypoxic pulmonary |
| HPASMCs | human pulmonary arterial smooth muscle cells |
| HPVECs | human primary vascular endothelial cells |
| ICAM-1 | intercellular adhesion molecule 1 |
| IL-10 | Interleukin 10 |
| IL-1β | Interleukin-1β |
| IL-6 | Interleukin 6 |
| iNOS | inducible nitric oxide synthase |
| %MWT | percentage medial wall thickness of pulmonary arteries |
| mCAP | mean carotid artery pressure |
| MCT | monocrotaline |
| MDA | malondialdehyde |
| MMP-2 | matrix metalloprotease 2 |
| MMP-9 | matrix metalloprotease 9 |
| mCAP | mean carotid arterial pressure |
| mPAP | mean pulmonary arterial pressure |
| mSAP | mean systemic arterial pressure |
| MVW | Medial wall thickness |
| MWT | medial wall thickness of pulmonary arteries |
| ND | not detected |
| NF-κB | nuclear factor κB |
| NFATc2 | calcineurin/nuclear factor of activated T cells c2 |
| NO | nitric oxide |
| NOX | NADPH oxidases |
| Nrf 2 | nuclear respiratory factor 2 |
| NRVM | neonatal rat ventricular myocyte |
| OPCs | oligometric proanthocyanidins |
| OPN | osteopontin |
| p27KIP1 | Cyclin-dependent kinase inhibitor 1B |
| p38 | 38.000-dalton membrane protein |
| p38MAPK | p38 mitogen-activated protein kinase |
| p-Akt | phosphorylated Akt |
| PA | pulmonary arterial |
| PABP | poly-A binding protein |
| PAEC | pulmonary arterials endothelial cells |
| PAH | pulmonary arterial hypertension |
| PAP | pulmonary artery pressure |
| PASMC | pulmonary arterial smooth muscle cell |
| PBP | pulmonary blood pressure |
| PCNA | protein content of proliferating nuclear cell antigen |
| PDE | phosphodiesterase enzyme |
| PDE5A | Phosphodiesterase type 5A enzyme |
| PDGF | platelet derived growth factor |
| PGI2 | prostaglandin I2 |
| PHT | pulmonary hypertension |
| PI3K | phosphoinositide-3- kinase |
| PKA | protein kinase A |
| PKB | protein kinase B |
| Pim1 | provirus integration site for Moloney murine leukemia virus 1 |
| PNS | Panax notoginseng Saponins |
| PP2Ac | protein phosphatase 2A catalytic subunit (Y307) |
| PTGS | prostaglandin-endoperoxide synthase |
| PVC | pulmonary vascular cell |
| PVR | pulmonary vessel resistance |
| RES | Resveratrol |
| RHF | right heart failure |
| ROS | reactive oxygen species |
| RV | right ventricle |
| RVEF | RV ejection fraction |
| RVH | right ventricular hypertrophy |
| RVHI | right ventricular hypertrophy index |
| RVSP | right ventricular systolic pressure |
| RV/ (LV+S) | ratio of right ventricle to the left ventricular plus interventricular septum |
| RV/TV ratio | right-to-total ventricular weight ratio |
| RV/BW | right ventricle to body weight ratio |
| RVP | right ventricular pressure |
| S | septum |
| SMAD3 | SMAD Family Member 3 |
| SDF-1 | stromal cell-derived factor 1 |
| SOCE | store-operated Ca2+ entry |
| SPA | small pulmonary arteries |
| SM22α | smooth muscle 22α |
| SOD-1 | superoxide dismutase 1 |
| Src | Proto-Oncogene, Non-Receptor Tyrosine Kinase |
| STAT3 | signal transducer and activator of transcription 3 |
| TAPSE | tricuspid annular plane systolic excursion |
| TBARS | thiobarbituric acid reactive substance |
| TGF-β1 | transforming growth factor 1 |
| TMS | trimethoxysilbene |
| TNF-α | Tumor necrosis factor α |
| TrkA | tropomyosin-related kinase A |
| Trx-1 | thioredoxin reductase 1 |
| TXA2 | thromboxane A2 |
| TxB2 | thromboxane B2 |
| VCAM-1 | vascular cell adhesion molecule 1 |
| VEF | ventricular ejection fraction |
| VEGF | vascular endothelial growth factor |
| VEGFA | vascular endothelial growth factor A |
| vWF | von Willebrand factor |